These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27686282)

  • 1. Electrocardiographic surveillance in a psychiatric institution: avoiding iatrogenic cardiovascular death.
    Rodríguez-Leal CM; López-Lunar E; Carrascosa-Bernáldez JM; Provencio-Arranz RM
    Int J Psychiatry Clin Pract; 2017 Mar; 21(1):64-66. PubMed ID: 27686282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.
    Girardin FR; Gex-Fabry M; Berney P; Shah D; Gaspoz JM; Dayer P
    Am J Psychiatry; 2013 Dec; 170(12):1468-76. PubMed ID: 24306340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
    Watanabe J; Suzuki Y; Fukui N; Ono S; Sugai T; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Feb; 32(1):18-22. PubMed ID: 22198445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic changes in patients receiving neuroleptic medication.
    Warner JP; Barnes TR; Henry JA
    Acta Psychiatr Scand; 1996 Apr; 93(4):311-3. PubMed ID: 8712033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
    Wilton LV; Heeley EL; Pickering RM; Shakir SA
    J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiological monitoring of antipsychotic-treated patients: evaluation and evolution of a hospital protocol].
    Frimas V; Roberge C; Perroux D; Dauvillier JM
    Encephale; 2008 Oct; 34(5):467-76. PubMed ID: 19068335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long QT syndrome due to olanzapine administration].
    Janion M; Dudek A; Sielski J; Janion-Sadowska A
    Kardiol Pol; 2006 Sep; 64(9):986-8. PubMed ID: 17054030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
    Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Psychiatric patients and QT interval monitoring].
    Girardin F; Gaspoz JM
    Rev Med Suisse; 2007 Apr; 3(106):945-8. PubMed ID: 17575970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of antipsychotics: a clinical overview.
    Polcwiartek C; Kragholm K; Schjerning O; Graff C; Nielsen J
    Expert Opin Drug Saf; 2016 May; 15(5):679-88. PubMed ID: 26934282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness.
    Manchia M; Firinu G; Carpiniello B; Pinna F
    BMC Psychiatry; 2017 Mar; 17(1):121. PubMed ID: 28359306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden arrhythmia death syndrome: importance of the long QT syndrome.
    Meyer JS; Mehdirad A; Salem BI; Kulikowska A; Kulikowski P
    Am Fam Physician; 2003 Aug; 68(3):483-8. PubMed ID: 12924831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.
    Petersen AB; Andersen SE; Christensen M; Larsen HL
    Clin Toxicol (Phila); 2014 Jan; 52(1):39-43. PubMed ID: 24313745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
    Czekalla J; Kollack-Walker S; Beasley CM
    J Clin Psychiatry; 2001; 62 Suppl 2():35-40. PubMed ID: 11232751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QTc-interval abnormalities in a forensic population.
    Girgis S; Huckstep B; Oakley J; Ferriter M; Nikolaou V
    Crim Behav Ment Health; 2007; 17(2):75-88. PubMed ID: 17295199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.
    Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):39-42. PubMed ID: 22144033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
    Gury C; Canceil O; Iaria P
    Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.